Shah, Neil P.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,760

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 947

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 769

Gene expression changes associated with progression and response in chronic myeloid leukemia

Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 583

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 446

Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 277

Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation

Cann, A. J., Rosenblatt, J. D., Wachsman, W., Shah, N. P., & Chen, I. S. Y. (1985) · Nature

T-cell and Retrovirus StudiesViral-associated cancers and disorders

Cited by 208

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Leyte-Vidal, A., Garrido Ruiz, D., DeFilippis, R., Leske, I. B., Rea, D., Phan, S., Miller, K. B., Hu, F., Mase, A., Shan, Y., et al. (2024) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 40

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

Shah, N. P., García‐Gutiérrez, V., Jiménez‐Velasco, A., Larson, S. M., Saussele, S., Rea, D., Mahon, F., Levy, M. Y., Gómez‐Casares, M. T., Mauro, M. J., et al. (2023) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 29

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib

Leyte-Vidal, A., DeFilippis, R., Outhwaite, I. R., Kwan, I., Lee, J. Y., Leavitt, C., Miller, K. B., Rea, D., Rangwala, A. M., Lou, K., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17